MedTrace Logo

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

NCT04821336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-05-01

No results posted yet for this study

Summary

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Conditions

Interventions

OTHER

Metabolites dosage

On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand. The investigators will compare the rate of deregulation between sane and malignant ones.

Sponsors & Collaborators

  • Cancer Research Center of Toulouse

    collaborator UNKNOWN

  • Institut Claudius Regaud

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821336 on ClinicalTrials.gov